HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.

Abstract
Our retrospective analysis compared the effectiveness of conventional antracycline-containing protocols (A+) and docetaxel/epirubicine (TE) as primary systemic chemotherapies (PSCT) for inflammatory breast cancer (IBC). Seventy IBC patients received either A + (n = 48) or TE (n = 22) as PSCT. The objective clinical response and clinical benefit rate of treated patients were 54.3% (A+: 54,2% vs. TE: 54,5%; p = 0,28) and 92.8% (A+: 91,7% vs. TE: 95,5%; p = 0,57), respectively. The clinical complete response rate (cCR) was 23.2% (A+: 27,1% vs. TE:4,5%; χ (2) = 4,79; p = 0,03) with 7.14% (A+: 10,4% vs. TE:0%; χ (2) = 2,47; p = 0,12) of pathological complete responses (pCR). The median progression free (PFS)/local progression free (LPFS)/overall survival (OS) was 2.0/5.4/4.0 years, respectively. Patients achieving cCR had a tendency for better survival parameters than patients with less than cCR. Response rates or survival data were not statistically different in the two chemotherapy (CT) treatment groups. The survival was not influenced by the number of CT cycles in either protocols. In this set of patients, the clinical efficacy of the two alternative primary systemic chemotherapies (A + and TE) is equivalent in the treatment of inflammatory breast cancer (IBC), despite of the significant difference in favour of A + noticed in CRs. Six cycles of CT could be enough for patients achieving CR, however sequential pre- and/or postoperative CT with non cross-resistant drugs should be considered for non-responders.
AuthorsZsolt Horváth, László Torday, Erika Hitre, Erna Ganofszky, Eva Juhos, Ferenc Czeglédi, László Urbán, Csaba Polgár, István Láng, Sándor Eckhardt, Miklós Kásler
JournalPathology oncology research : POR (Pathol Oncol Res) Vol. 17 Issue 3 Pg. 541-50 (Sep 2011) ISSN: 1532-2807 [Electronic] Switzerland
PMID21153723 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anthracyclines
  • Taxoids
  • Docetaxel
  • Epirubicin
Topics
  • Adult
  • Aged
  • Anthracyclines (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Case-Control Studies
  • Docetaxel
  • Epirubicin (administration & dosage)
  • Female
  • Follow-Up Studies
  • Humans
  • Inflammatory Breast Neoplasms (drug therapy, pathology)
  • Middle Aged
  • Retrospective Studies
  • Survival Rate
  • Taxoids (administration & dosage)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: